Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
892.5 USD | +1.05% | -0.85% | +1.62% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.62% | 96.29B | |
-2.63% | 102B | |
+2.62% | 22.18B | |
-16.67% | 21.2B | |
-9.19% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B | |
-24.98% | 8.21B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals : to Supply U.S. Government with up to 1.25 Million Doses of Covid-19 Antibody Therapy; Agreement Worth up to $2.625 Billion